Committed to Improving the Lives of Chronically Ill Patients

Located in Watertown, MA, Excision BioTherapeutics, Inc. is a biotechnology company developing CRISPR-based therapies intended for the treatment of viral infectious diseases. We are focused on improving the lives of chronically ill patients by excising viral genomes from infected individuals. By using CRISPR in unique ways, we have already demonstrated the first functional therapeutic treatment for HIV in animals.

Featuring A Proprietary Dual Cut Approach

Our cutting-edge CRISPR gene therapy platform is built on technology licensed from the Doudna Lab at UC Berkeley and the Khalili Lab at Temple University. We are the first company to remove HIV genomes from animals and generate functional therapeutic treatments for HIV.

About Our Technology

CRISPR-based Programs Selective for Specific Genomes

Our rapidly progressing pipeline targets viral infectious diseases, including human immunodeficiency virus (HIV), herpes simplex viruses (HSV 1&2), and Hepatitis B.

View Our Pipeline

Targeting Large Markets with Significant Unmet Medical Needs

Excision Chart

Current therapies are not curative and have significant safety, tolerability, and price challenges.



~38 million HIV cases worldwide1

Target Population

Stable on Anti-Retroviral Therapy (ART)

Standard of Care

Antiretrovirals (non-curative)

HSV 1&2


~3.7 billion HSV-1 cases,

~492 million HSV-2 cases worldwide3

Target Population

Recurrent infection

Standard of Care

Antivirals (non-curative) 



~350 million patients worldwide4

Target Population

Progressive infection

Standard of Care

Vaccine; Antivirals (non-curative)

Sources: 1 AIDS. 2017 Jan 28; 31; 2 NORD. 2021; 3 WHO 2020; 4 CDC, 13 2021.

Excision’s Extensive Intellectual Property

Over 25 Patent Families Covering:

  • Platform: viral excision, retroviral excision, lentiviral excision, targeting-specific
  • Product development software
  • Human infectious viruses (virus-specific families)
  • Sequences, compositions, methods
  • University of California, Berkeley CRISPR exclusive license for viral infectious diseases

UC Berkeley Next-generation CRISPR Nucleases:

  • All viral infectious diseases
  • CasX (Cas12e)
  • CasY (Cas12d)

Led By the Brightest Minds in Science

Our team comprises numerous experts in molecular biology, regulatory management, and clinical development.

View Leadership Team View Board of Directors View R&D Partners View Scientific Advisory Board View Business Advisory Board

Research-driven Partnerships

We are supported by various partners, inlcuding ARTIS Ventures, GreatPoint Ventures, Norwest Venture Partners, Adjuvant Capital, Cota Capital, Celesta Capital IndusAge Partners, Loreda Holdings, Olive Tree, Anzu Partners, SilverRidge Venture Partners, Oakhouse Ventures, and Gaingels.